ndividuals with spontaneous loss-of-function PCSK9 mutations experience a significant reduction of both LDL-C levels (30–40%) as well as CHD risk (88%), and appear free from adverse clinical consequences.2 Gene-editing technologies, which include the CRISPR–Cas nucleases and CRISPR base editor, have the potential to permanently modify disease-causing genes.
A 'once-and-done' approach to the lifelong reduction of elevated cholesterol / Paneni, Francesco; Volpe, Massimo. - In: EUROPEAN HEART JOURNAL. - ISSN 1522-9645. - 42:37(2021), pp. 3820-3821. [10.1093/eurheartj/ehab478]
A 'once-and-done' approach to the lifelong reduction of elevated cholesterol
Paneni, Francesco;Volpe, Massimo
2021
Abstract
ndividuals with spontaneous loss-of-function PCSK9 mutations experience a significant reduction of both LDL-C levels (30–40%) as well as CHD risk (88%), and appear free from adverse clinical consequences.2 Gene-editing technologies, which include the CRISPR–Cas nucleases and CRISPR base editor, have the potential to permanently modify disease-causing genes.File allegati a questo prodotto
| File | Dimensione | Formato | |
|---|---|---|---|
|
Paneni_A-Once_2021.pdf
accesso aperto
Tipologia:
Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza:
Tutti i diritti riservati (All rights reserved)
Dimensione
192.64 kB
Formato
Adobe PDF
|
192.64 kB | Adobe PDF |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
